- Home
- EYPT vs INVA Comparison
EYPT vs INVA Comparison
Compare EYPT & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- INVA
- Stock Information
- Founded
- EYPT 1987
- INVA 1996
- Country
- EYPT United States
- INVA United States
- Employees
- EYPT N/A
- INVA N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- INVA Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- INVA Health Care
- Exchange
- EYPT Nasdaq
- INVA Nasdaq
- Market Cap
- EYPT 967.4M
- INVA 1.1B
- IPO Year
- EYPT 2005
- INVA 2004
- Fundamental
- Price
- EYPT $11.76
- INVA $17.71
- Analyst Decision
- EYPT Strong Buy
- INVA Buy
- Analyst Count
- EYPT 5
- INVA 5
- Target Price
- EYPT $27.40
- INVA $35.60
- AVG Volume (30 Days)
- EYPT 1.4M
- INVA 767.7K
- Earning Date
- EYPT 11-05-2025
- INVA 11-06-2025
- Dividend Yield
- EYPT N/A
- INVA N/A
- EPS Growth
- EYPT N/A
- INVA N/A
- EPS
- EYPT N/A
- INVA 0.53
- Revenue
- EYPT $51,898,000.00
- INVA $370,229,000.00
- Revenue This Year
- EYPT N/A
- INVA $7.98
- Revenue Next Year
- EYPT N/A
- INVA $11.60
- P/E Ratio
- EYPT N/A
- INVA $32.96
- Revenue Growth
- EYPT 2.99
- INVA 12.02
- 52 Week Low
- EYPT $3.91
- INVA $16.52
- 52 Week High
- EYPT $14.91
- INVA $22.00
- Technical
- Relative Strength Index (RSI)
- EYPT 42.93
- INVA 46.40
- Support Level
- EYPT $11.15
- INVA $17.45
- Resistance Level
- EYPT $12.47
- INVA $18.45
- Average True Range (ATR)
- EYPT 0.68
- INVA 0.50
- MACD
- EYPT -0.08
- INVA 0.12
- Stochastic Oscillator
- EYPT 23.37
- INVA 52.42
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.